Glabridin Exhibits Potent Inhibitory Effects Against Toxoplasma Gondii in Vitro and in Vivo

Overview

Journal Parasit Vectors

Publisher Biomed Central

Specialties Parasitology
Tropical Medicine

Date 2024 Dec 19

PMID 39695816

Authors

Lu Wang

Bintao Zhai

Chen Wang

Hany M Elsheikha

Haiting Guo

Xiao-Nan Zheng

Chun-Xue Zhou

Xing-Quan Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Toxoplasma gondii is an obligate protozoan parasite capable of infecting a wide range of warm-blooded animals and humans. Current treatment options, primarily pyrimethamine and sulfadiazine, have limitations, such as high recurrence rates, long treatment durations, and limited effectiveness against T. gondii. There is an unmet need for novel, safe, low-toxicity, and highly effective treatments. This study aimed to evaluate the anti-T. gondii effects of glabridin, a natural compound derived from the roots of a widely used medicinal plant.

Methods: The cytotoxicity of glabridin in Vero cells was assessed using a CCK-8 cell viability assay. Quantitative polymerase chain reaction (qPCR) targeting the Tg-529 gene was developed to quantify T. gondii and assess the inhibitory effects of glabridin on parasite proliferation. Ultrastructural changes in T. gondii after treatment were examined using electron microscopy. The levels of reactive oxygen species (ROS) and mitochondrial membrane potential (ΔΨm) were examined to assess the effects of glabridin on ROS levels and ΔΨm in T. gondii tachyzoites. Additionally, metabolomics and transcriptomics analyses were conducted to investigate the mechanisms underlying glabridin's anti-T. gondii effects.

Results: Glabridin exhibited low toxicity to host cells and effectively inhibited T. gondii invasion and proliferation in vitro in a time-dependent manner. Glabridin-treated tachyzoites exhibited significant structural alterations, along with increased ROS production and a reduction in ΔΨm. Metabolomic analysis indicated that glabridin significantly affected amino acid metabolism pathways in T. gondii. In vivo, glabridin treatment significantly improved survival rates in T. gondii-infected BALB/c mice at a dosage of 100 mg/kg.

Conclusions: This study demonstrates that glabridin has potent anti-T. gondii effects in vitro and in vivo, likely through disruption of amino acid metabolism in the parasite. These findings highlight glabridin's potential as a promising therapeutic agent for toxoplasmosis.

References

Wahab S, Annadurai S, Abullais S, Das G, Ahmad W, Ahmad M . (Licorice): A Comprehensive Review on Its Phytochemistry, Biological Activities, Clinical Evidence and Toxicology. Plants (Basel). 2021; 10(12). PMC: 8703329. DOI: 10.3390/plants10122751. View

Chen X, Elsheikha H, Hu R, Hu G, Guo S, Zhou C . Hepatic Metabolomics Investigation in Acute and Chronic Murine Toxoplasmosis. Front Cell Infect Microbiol. 2018; 8:189. PMC: 5996072. DOI: 10.3389/fcimb.2018.00189. View

Robles-Remacho A, Sanchez-Martin R, Diaz-Mochon J . Spatial Transcriptomics: Emerging Technologies in Tissue Gene Expression Profiling. Anal Chem. 2023; 95(42):15450-15460. PMC: 10603609. DOI: 10.1021/acs.analchem.3c02029. View

Parlar A, Arslan S, Cam S . Glabridin Alleviates Inflammation and Nociception in Rodents by Activating BK Channels and Reducing NO Levels. Biol Pharm Bull. 2020; 43(5):884-897. DOI: 10.1248/bpb.b20-00038. View

Dubey J, Murata F, Cerqueira-Cezar C, Kwok O, Villena I . Congenital toxoplasmosis in humans: an update of worldwide rate of congenital infections. Parasitology. 2021; 148(12):1406-1416. PMC: 11010219. DOI: 10.1017/S0031182021001013. View

Belinky P, Aviram M, Fuhrman B, Rosenblat M, Vaya J . The antioxidative effects of the isoflavan glabridin on endogenous constituents of LDL during its oxidation. Atherosclerosis. 1998; 137(1):49-61. DOI: 10.1016/s0021-9150(97)00251-7. View

Kim S, Kim S, Kim J, Hwang S, Yoo H . Understanding Metabolomics in Biomedical Research. Endocrinol Metab (Seoul). 2015; 31(1):7-16. PMC: 4803564. DOI: 10.3803/EnM.2016.31.1.7. View

Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M . KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2020; 49(D1):D545-D551. PMC: 7779016. DOI: 10.1093/nar/gkaa970. View

Milne G, Webster J, Walker M . Toxoplasma gondii: AnUnderestimated Threat?. Trends Parasitol. 2020; 36(12):959-969. DOI: 10.1016/j.pt.2020.08.005. View

10.

Nolan S, Romano J, Coppens I . Host lipid droplets: An important source of lipids salvaged by the intracellular parasite Toxoplasma gondii. PLoS Pathog. 2017; 13(6):e1006362. PMC: 5469497. DOI: 10.1371/journal.ppat.1006362. View

11.

Ye Q, Zhang Q, Yao H, Xu A, Liu Y, Qi J . Active-Ingredient Screening and Synergistic Action Mechanism of Shegan Mixture for Anti-Asthma Effects Based on Network Pharmacology in a Mouse Model of Asthma. Drug Des Devel Ther. 2021; 15:1765-1777. PMC: 8092947. DOI: 10.2147/DDDT.S288829. View

12.

Zhou C, Gan Y, Elsheikha H, Chen X, Cong H, Liu Q . Sulfadiazine Sodium Ameliorates the Metabolomic Perturbation in Mice Infected with Toxoplasma gondii. Antimicrob Agents Chemother. 2019; 63(10). PMC: 6761496. DOI: 10.1128/AAC.00312-19. View

13.

McAuley J . Congenital Toxoplasmosis. J Pediatric Infect Dis Soc. 2014; 3 Suppl 1:S30-5. PMC: 4164182. DOI: 10.1093/jpids/piu077. View

14.

Atanasov A, Zotchev S, Dirsch V, Supuran C . Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021; 20(3):200-216. PMC: 7841765. DOI: 10.1038/s41573-020-00114-z. View

15.

Sidik S, Huet D, Ganesan S, Huynh M, Wang T, Nasamu A . A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Cell. 2016; 166(6):1423-1435.e12. PMC: 5017925. DOI: 10.1016/j.cell.2016.08.019. View

16.

Dubois D, Fernandes S, Amiar S, Dass S, Katris N, Botte C . acetyl-CoA synthetase is involved in fatty acid elongation (of long fatty acid chains) during tachyzoite life stages. J Lipid Res. 2018; 59(6):994-1004. PMC: 5983401. DOI: 10.1194/jlr.M082891. View

17.

Sharif M, Sarvi S, Pagheh A, Asfaram S, Rahimi M, Mehrzadi S . The efficacy of herbal medicines against Toxoplasma gondii during the last 3 decades: a systematic review. Can J Physiol Pharmacol. 2016; 94(12):1237-1248. DOI: 10.1139/cjpp-2016-0039. View

18.

Ramakrishnan S, Docampo M, MacRae J, Pujol F, Brooks C, van Dooren G . Apicoplast and endoplasmic reticulum cooperate in fatty acid biosynthesis in apicomplexan parasite Toxoplasma gondii. J Biol Chem. 2011; 287(7):4957-71. PMC: 3281623. DOI: 10.1074/jbc.M111.310144. View

19.

Schmidt D, Hogh B, Andersen O, Hansen S, Dalhoff K, Petersen E . Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine. Eur J Pediatr. 2005; 165(1):19-25. DOI: 10.1007/s00431-005-1665-4. View

20.

Leesombun A, Nihei C, Kondoh D, Nishikawa Y . Polyether ionophore kijimicin inhibits growth of Toxoplasma gondii and controls acute toxoplasmosis in mice. Parasitol Res. 2021; 121(1):413-422. DOI: 10.1007/s00436-021-07363-w. View